- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06945718
Wyniki kliniczne zielonego znacznika indocyjaniny przy użyciu laparoskopowej gastrektomii z przedłużoną limfadenektomią poza D2 dla lokalnie zaawansowanego raka żołądka (FUGES-30)
Prospektywne randomizowane kontrolowane badania dotyczące wyników klinicznych zielonego znacznika indocyjaninowego stosowania w laparoskopowej gastrektomii z rozwarstwieniem węzła chłonnego D2 dla lokalnie zaawansowanego raka żołądka (FUGES-30)
Taking patients with locally advanced gastric adenocarcinoma (cT2-4a, N-/+, M0) as the research subjects, to evaluate whether the clinical efficacy of laparoscopic beyond D2 regional lymph node dissection for gastric cancer with indocyanine green tracer is better or not.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Typ studiów
Zapisy (Szacowany)
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Mi Lin, phD
- Numer telefonu: 13459152658
- E-mail: silihuala@qq.com
Kopia zapasowa kontaktu do badania
- Nazwa: Hua-Long Zheng, phD
- Numer telefonu: 18359190587
- E-mail: 291167038@qq.com
Lokalizacje studiów
-
-
Fujian
-
Fuzhou, Fujian, Chiny, 350001
- Rekrutacyjny
- Fujian Medical University Union Hospital
-
Kontakt:
- Changming Huang, M.D., Ph.D.
- Numer telefonu: +86-133-6591-0253
- E-mail: hcmlr2002@163.com
-
Główny śledczy:
- Changming Huang, M.D., Ph.D.
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Age from 18 to 75 years Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy cT2-4a, N-/+, M0 at preoperative evaluation according to the AJCC Cancer Staging Manual, 8th Edition
Opis
Inclusion Criteria:
Age from 18 to 75 years Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically by endoscopic biopsy cT2-4a, N-/+, M0 at preoperative evaluation according to the AJCC Cancer Staging Manual, 8th Edition No distant metastasis, no direct invasion of pancreas, spleen or other adjacent organs in the preoperative examinations Performance status of 0 or 1 on the ECOG (Eastern Cooperative Oncology Group) scale ASA (American Society of Anesthesiology) class I to III Written informed consent
Exclusion Criteria:
Women during pregnancy or breast-feeding Severe mental disorder History of previous upper abdominal surgery (except for laparoscopic cholecystectomy) History of previous gastric surgery (including ESD/EMR for gastric cancer) Enlarged or bulky regional lymph node (diameter over 3cm) supported by preoperative imaging including enlarged or bulky lymph nodes in D3 region.
Other malignant disease within the past 5 years History of unstable angina or myocardial infarction within past six months History of cerebrovascular accident within past six months History of continuous systematic administration of corticosteroids within one month Requirement for simultaneous surgery for other disease Emergency surgery due to complication (bleeding, obstruction or perforation) caused by gastric cancer FEV1 (forced expiratory volume in one second)<50% of predicted values Diffuse invasive gastric cancer Tumors preoperatively confirmed to involve the squamocolumnar junction or duodenum History of an iodine allergy Patients who declined laparoscopic surgery
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Kohorty i interwencje
Grupa / Kohorta |
Interwencja / Leczenie |
|---|---|
|
laparoscopic gastrectomy with beyond D2 regional fluorescent lymph node dissection with ICG group
ICG with D2+ group |
dissect the lymph nodes outside the extent of D2 LN region. |
|
laparoscopic gastrectomy with D2 regional lymph node dissection with ICG group
ICG with D2 group |
dissect the lymph nodes outside the extent of D2 LN region. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
3-year disease free survival rate
Ramy czasowe: 3 years
|
Disease-free survival is calculated from the day of surgery to the day of recurrence or death |
3 years
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Total number of retrieved lymph nodes
Ramy czasowe: 30 days
|
Total number of retrieved lymph nodes |
30 days
|
|
Noncompliance rate of lymph node dissection
Ramy czasowe: 30 days
|
The LN dissection rate was determined by the number of patients in whom a LN station was harvested divided by the total number of patients who required retrieval at the corresponding LN station. Within the scope of D2 dissection, LN noncompliance was defined as the absence of LNs that should have been resected from > 1 LN station. |
30 days
|
|
Relationship between fluorescent lymph nodes in group A and total number of lymph nodes in group A
Ramy czasowe: 30 days
|
Relationship between the number of fluorescent lymph nodes in group A and total number of lymph nodes in group A |
30 days
|
|
Relationship between fluorescent lymph nodes in Group A and positive lymph nodes in Group A (positive rate)
Ramy czasowe: 30 days
|
The number of positive lymph nodes in fluorescent lymph nodes is divided by the number of total fluorescent lymph nodes in Group A (True positive rate). |
30 days
|
|
Relationship between fluorescent lymph nodes in Group A and negative lymph nodes in Group A (false positive rate)
Ramy czasowe: 30 days
|
The number of negative lymph nodes in fluorescent lymph nodes is divided by the number of total fluorescent lymph nodes in Group A (false positive rate). |
30 days
|
|
Relationship between non-fluorescent lymph nodes in Group A and negative lymph nodes in group A (negative rate)
Ramy czasowe: 30 days
|
The number of negative lymph nodes in not fluorescent lymph nodes is divided by the number of total not fluorescent lymph nodes in group A (True negative rate). |
30 days
|
|
Relationship between nonfluorescent lymph nodes in Group A and positive lymph nodes in Group A (false negative rate)
Ramy czasowe: 30 days
|
The number of positive lymph nodes in not fluorescent lymph nodes is divided by the number of total not fluorescent lymph nodes in Group A (false negative rate). |
30 days
|
|
Relationship between fluorescent lymph nodes in group B and total number of lymph nodes in group B
Ramy czasowe: 30 days
|
Relationship between the number of fluorescent lymph nodes in group B and total number of lymph nodes in group B |
30 days
|
|
Relationship between fluorescent lymph nodes in Group B and positive lymph nodes in Group B (positive rate)
Ramy czasowe: 30 days
|
The number of positive lymph nodes in fluorescent lymph nodes is divided by the number of total fluorescent lymph nodes in Group B (True positive rate). |
30 days
|
|
Relationship between fluorescent lymph nodes in Group B and negative lymph nodes in Group B (false positive rate)
Ramy czasowe: 30 days
|
The number of negative lymph nodes in fluorescent lymph nodes is divided by the number of total fluorescent lymph nodes in Group A (false positive rate). |
30 days
|
|
Relationship between non-fluorescent lymph nodes in Group B and negative lymph nodes in group B (negative rate)
Ramy czasowe: 30 days
|
The number of negative lymph nodes in not fluorescent lymph nodes is divided by the number of total not fluorescent lymph nodes in group B (True negative rate). |
30 days
|
|
Relationship between nonfluorescent lymph nodes in Group B and positive lymph nodes in Group B (false negative rate)
Ramy czasowe: 30 days
|
The number of positive lymph nodes in not fluorescent lymph nodes is divided by the number of total not fluorescent lymph nodes in Group B (false negative rate). |
30 days
|
|
Number of metastatic lymph nodes
Ramy czasowe: 30 days
|
Number of metastatic lymph nodes |
30 days
|
|
Metastasis rate of lymph nodes
Ramy czasowe: 30 days
|
Metastasis rate of lymph nodes |
30 days
|
|
Postoperative complications
Ramy czasowe: 30 days
|
Postoperative complications were evaluated within 30 days following surgery. These postoperative complications include gastrointestinal-related complications, incision-related complications, respiratory complications, cardiovascular and cerebrovascular complications, urinary system complications, infection complications, embolism complications, and other complications. The grading of postoperative complications adopts the Clavien-Dindo classification. |
30 days
|
|
Mortality rates
Ramy czasowe: 30 days
|
Patient died during hospitalization. |
30 days
|
|
3-year overall survival rate
Ramy czasowe: 3 years
|
3-year overall survival rate |
3 years
|
|
3-year recurrence pattern
Ramy czasowe: 3 years
|
3-year recurrence pattern |
3 years
|
|
Postoperative recovery course
Ramy czasowe: 30 days
|
Time to first flatus after surgery, time to first ambulation after surgery, time to first liquid diet after surgery, time to first semi-liquid diet after surgery, length of hospital stay after surgery. |
30 days
|
|
The incidence of intraoperative complications
Ramy czasowe: 30 days
|
Intraoperative complications were defined as bleeding due to named vessel injury, injury to visceral organs, mechanical factor-related problems, cardiopulmonary dysfunction due to hypercapnia, and other complications |
30 days
|
|
Inflammatory and immune response
Ramy czasowe: 7 days
|
the values of hemoglobin, prealbumin, albumin, C-reactive protein, and white blood cell count from peripheral blood before the operation and on postoperative day 1, 3, 5 are recorded. |
7 days
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Chang-Ming Huang, Prof., Fujian Medical University Union Hospital
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- FUGES-30
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .